Cargando…

Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis

BACKGROUND: There is a paucity of data on the health care costs of antiretroviral therapy (ART) programmes in Africa. Our objectives were to describe the direct heath care costs and establish the cost drivers over time in an HIV managed care programme in Southern Africa. METHODS/FINDINGS: We analyse...

Descripción completa

Detalles Bibliográficos
Autores principales: Leisegang, Rory, Cleary, Susan, Hislop, Michael, Davidse, Alistair, Regensberg, Leon, Little, Francesca, Maartens, Gary
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777319/
https://www.ncbi.nlm.nih.gov/pubmed/19956658
http://dx.doi.org/10.1371/journal.pmed.1000189
_version_ 1782174172813721600
author Leisegang, Rory
Cleary, Susan
Hislop, Michael
Davidse, Alistair
Regensberg, Leon
Little, Francesca
Maartens, Gary
author_facet Leisegang, Rory
Cleary, Susan
Hislop, Michael
Davidse, Alistair
Regensberg, Leon
Little, Francesca
Maartens, Gary
author_sort Leisegang, Rory
collection PubMed
description BACKGROUND: There is a paucity of data on the health care costs of antiretroviral therapy (ART) programmes in Africa. Our objectives were to describe the direct heath care costs and establish the cost drivers over time in an HIV managed care programme in Southern Africa. METHODS/FINDINGS: We analysed the direct costs of treating HIV-infected adults enrolled in the managed care programme from 3 years before starting non-nucleoside reverse transcriptase inhibitor-based ART up to 5 years afterwards. The CD4 cell count criterion for starting ART was <350 cells/µl. We explored associations between variables and mean total costs over time using a generalised linear model with a log-link function and a gamma distribution. Our cohort consisted of 10,735 patients (59.4% women) with 594,497 mo of follow up data (50.9% of months on ART). Median baseline CD4+ cell count and viral load were 125 cells/µl and 5.16 log(10) copies/ml respectively. There was a peak in costs in the period around ART initiation (from 4 mo before until 4 mo after starting ART) driven largely by hospitalisation, following which costs plateaued for 5 years. The variables associated with changes in mean total costs varied with time. Key early associations with higher costs were low baseline CD4+ cell count, high baseline HIV viral load, and shorter duration in HIV care prior to starting ART; whilst later associations with higher costs were lower ART adherence, switching to protease inhibitor-based ART, and starting ART at an older age. CONCLUSIONS: Drivers of mean total costs changed considerably over time. Starting ART at higher CD4 counts or longer pre-ART care should reduce early costs. Monitoring ART adherence and interventions to improve it should reduce later costs. Cost models of ART should take into account these time-dependent cost drivers, and include costs before starting ART. Please see later in the article for the Editors' Summary
format Text
id pubmed-2777319
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-27773192009-12-03 Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis Leisegang, Rory Cleary, Susan Hislop, Michael Davidse, Alistair Regensberg, Leon Little, Francesca Maartens, Gary PLoS Med Research Article BACKGROUND: There is a paucity of data on the health care costs of antiretroviral therapy (ART) programmes in Africa. Our objectives were to describe the direct heath care costs and establish the cost drivers over time in an HIV managed care programme in Southern Africa. METHODS/FINDINGS: We analysed the direct costs of treating HIV-infected adults enrolled in the managed care programme from 3 years before starting non-nucleoside reverse transcriptase inhibitor-based ART up to 5 years afterwards. The CD4 cell count criterion for starting ART was <350 cells/µl. We explored associations between variables and mean total costs over time using a generalised linear model with a log-link function and a gamma distribution. Our cohort consisted of 10,735 patients (59.4% women) with 594,497 mo of follow up data (50.9% of months on ART). Median baseline CD4+ cell count and viral load were 125 cells/µl and 5.16 log(10) copies/ml respectively. There was a peak in costs in the period around ART initiation (from 4 mo before until 4 mo after starting ART) driven largely by hospitalisation, following which costs plateaued for 5 years. The variables associated with changes in mean total costs varied with time. Key early associations with higher costs were low baseline CD4+ cell count, high baseline HIV viral load, and shorter duration in HIV care prior to starting ART; whilst later associations with higher costs were lower ART adherence, switching to protease inhibitor-based ART, and starting ART at an older age. CONCLUSIONS: Drivers of mean total costs changed considerably over time. Starting ART at higher CD4 counts or longer pre-ART care should reduce early costs. Monitoring ART adherence and interventions to improve it should reduce later costs. Cost models of ART should take into account these time-dependent cost drivers, and include costs before starting ART. Please see later in the article for the Editors' Summary Public Library of Science 2009-12-01 /pmc/articles/PMC2777319/ /pubmed/19956658 http://dx.doi.org/10.1371/journal.pmed.1000189 Text en Leisegang et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Leisegang, Rory
Cleary, Susan
Hislop, Michael
Davidse, Alistair
Regensberg, Leon
Little, Francesca
Maartens, Gary
Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
title Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
title_full Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
title_fullStr Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
title_full_unstemmed Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
title_short Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
title_sort early and late direct costs in a southern african antiretroviral treatment programme: a retrospective cohort analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777319/
https://www.ncbi.nlm.nih.gov/pubmed/19956658
http://dx.doi.org/10.1371/journal.pmed.1000189
work_keys_str_mv AT leisegangrory earlyandlatedirectcostsinasouthernafricanantiretroviraltreatmentprogrammearetrospectivecohortanalysis
AT clearysusan earlyandlatedirectcostsinasouthernafricanantiretroviraltreatmentprogrammearetrospectivecohortanalysis
AT hislopmichael earlyandlatedirectcostsinasouthernafricanantiretroviraltreatmentprogrammearetrospectivecohortanalysis
AT davidsealistair earlyandlatedirectcostsinasouthernafricanantiretroviraltreatmentprogrammearetrospectivecohortanalysis
AT regensbergleon earlyandlatedirectcostsinasouthernafricanantiretroviraltreatmentprogrammearetrospectivecohortanalysis
AT littlefrancesca earlyandlatedirectcostsinasouthernafricanantiretroviraltreatmentprogrammearetrospectivecohortanalysis
AT maartensgary earlyandlatedirectcostsinasouthernafricanantiretroviraltreatmentprogrammearetrospectivecohortanalysis